Literature DB >> 30673814

Preoperative Leucocyte-Based Inflammatory Scores in Patients with Colorectal Liver Metastases: Can We Count on Them?

Aurélien Dupré1,2, Robert P Jones3,4, Rafael Diaz-Nieto3, Stephen W Fenwick3, Graeme J Poston3, Hassan Z Malik3.   

Abstract

BACKGROUND: Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR) have been identified as potential prognostic factors for overall survival (OS) in primary colorectal cancer, and there is a growing interest in their use in colorectal liver metastases (CLMs). However, optimal cut-off values for these ratios have not been defined by making comparison between series difficult. This study aimed to confirm the prognostic value of inflammatory scores in patients undergoing resection for CLM.
METHODS: We retrospectively analysed data from 376 consecutive patients who underwent liver surgery for CLM between June 2010 and August 2015. We assessed the reproducibility of previously published ratios and determined new cut-off values using the Cut-off Finder web-based tool. Relations between cut-off values and OS were analysed with Kaplan-Meier log-rank survival analysis and multivariate Cox models.
RESULTS: Three hundred and forty-three patients had full preoperative blood tests for calculation of NLR, PLR and LMR. The number of cut-off values which showed a significant discrimination for OS was 49/249 (19.7%) for NLR, 28/316 (8.9%) for PLR and 22/214 (10.3%) for LMR, all with a scattered nonlinear distribution.
CONCLUSIONS: This study showed that inflammatory scores expressed as ratios do not seem to be consistently reliable prognostic markers in patients with resectable CLM.

Entities:  

Mesh:

Year:  2019        PMID: 30673814     DOI: 10.1007/s00268-019-04914-2

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  28 in total

1.  Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.

Authors:  Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Murielle Mauer; Erik Tanis; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger
Journal:  Lancet Oncol       Date:  2013-10-11       Impact factor: 41.316

2.  Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor.

Authors:  Kyriakos Neofytou; Elizabeth C Smyth; Alexandros Giakoustidis; Aamir Z Khan; David Cunningham; Satvinder Mudan
Journal:  Med Oncol       Date:  2014-09-14       Impact factor: 3.064

3.  FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.

Authors:  C Cremolini; F Loupakis; G Masi; S Lonardi; C Granetto; M L Mancini; S Chiara; R Moretto; D Rossini; S Vitello; G Allegrini; G Tonini; F Bergamo; G Tomasello; M Ronzoni; A Buonadonna; S Bustreo; C Barbara; L Boni; A Falcone
Journal:  Ann Oncol       Date:  2016-02-09       Impact factor: 32.976

Review 4.  Precision surgery for colorectal liver metastases: Opportunities and challenges of omics-based decision making.

Authors:  R P Jones; K W Brudvik; J M Franklin; G J Poston
Journal:  Eur J Surg Oncol       Date:  2017-03-06       Impact factor: 4.424

5.  Colorectal Cancer, Systemic Inflammation, and Outcome: Staging the Tumor and Staging the Host.

Authors:  James H Park; David G Watt; Campbell S D Roxburgh; Paul G Horgan; Donald C McMillan
Journal:  Ann Surg       Date:  2016-02       Impact factor: 12.969

Review 6.  Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability.

Authors:  Francesco Colotta; Paola Allavena; Antonio Sica; Cecilia Garlanda; Alberto Mantovani
Journal:  Carcinogenesis       Date:  2009-05-25       Impact factor: 4.944

7.  An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study.

Authors:  M J Proctor; D S Morrison; D Talwar; S M Balmer; D S J O'Reilly; A K Foulis; P G Horgan; D C McMillan
Journal:  Br J Cancer       Date:  2011-01-25       Impact factor: 7.640

8.  Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization.

Authors:  Jan Budczies; Frederick Klauschen; Bruno V Sinn; Balázs Győrffy; Wolfgang D Schmitt; Silvia Darb-Esfahani; Carsten Denkert
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

Review 9.  Prognostic role of platelet-lymphocyte ratio in colorectal cancer: A systematic review and meta-analysis.

Authors:  Dewen Tan; Yan Fu; Qi Su; Heling Wang
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

10.  The Lymphocyte-to-Monocyte Ratio is a Superior Predictor of Overall Survival in Comparison to Established Biomarkers of Resectable Colorectal Cancer.

Authors:  Joseph C Y Chan; David L Chan; Connie I Diakos; Alexander Engel; Nick Pavlakis; Anthony Gill; Stephen J Clarke
Journal:  Ann Surg       Date:  2017-03       Impact factor: 12.969

View more
  3 in total

1.  Systemic Immune-Inflammation Index Predicts Overall Survival in Patients with Gastric Cancer: a Propensity Score-Matched Analysis.

Authors:  Noriyuki Hirahara; Yoshitsugu Tajima; Takeshi Matsubara; Yusuke Fujii; Shunsuke Kaji; Yasunari Kawabata; Ryoji Hyakudomi; Tetsu Yamamoto; Yuki Uchida; Takahito Taniura
Journal:  J Gastrointest Surg       Date:  2020-06-30       Impact factor: 3.452

2.  High Neutrophil-To-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammation Index (SII) Are Markers of Longer Survival After Metastasectomy of Patients With Liver-Only Metastasis of Rectal Cancer.

Authors:  Nándor Polk; Barna Budai; Erika Hitre; Attila Patócs; Tamás Mersich
Journal:  Pathol Oncol Res       Date:  2022-04-27       Impact factor: 2.874

3.  The prognostic utility of pre-treatment neutrophil-to-lymphocyte-ratio (NLR) in colorectal cancer: A systematic review and meta-analysis.

Authors:  Mate Naszai; Alina Kurjan; Timothy S Maughan
Journal:  Cancer Med       Date:  2021-07-26       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.